Community memory screening as a strategy for recruiting older adults into Alzheimer’s disease research
»
Community memory screening as a strategy for recruiting older adults into Alzheimer’s disease research
Background: Growing awareness of Alzheimer’s disease (AD) has boosted demand for quick and effective way to screen for memory loss and cognitive decline in a large number of individuals in society. Periodic Memory Screening Day events provide free, brief cognitive screening is intended for those 65 years and older, and can serve as an opportunity for participants to measure attitudes toward AD research and recruit them into research projects ongoing.
Methods: Over 6 one-day event in two years, more than 574 people individually filtered using a Moca and assignment story recall (immediate and delayed), are given feedback on their performance, and introduced the AD research and opportunities to participate.
Results: Screening classified 297 individuals (52.0%) as having “No Decline,” 192 (33.6%) as “The possibility of a decrease,” and 82 (14.4%) as “Likely decline.” Those with a “decline Likely” older and less educated, have more memory concerns, are more likely to be male, and less likely to have a positive family history of dementia compared with “No Decline.” subsequent validation of a screening procedure to full clinical evaluation revealed 72% classification accuracy with a leaning toward more-calling Possible and Likely reduction and thus guiding people questioned for a more thorough evaluation.
Of those screened, 378 (66%) agreed to additional research and approve research recorded in the registry, and the majority (70-85%) of approving reported they agreed to research the various AD procedures including lumbar puncture, MRI, and autopsy. Overall, 19.1% of those screened met the inclusion criteria for the ongoing study and successfully recruited to the study of AD.
Conclusion: Conducting the public memory is concentrated several screening events every year to help meet the public demand for a brief assessment of memory concerns and can be relatively effective recruitment strategies and efficient for AD research.
Attractive New Investigator Research into Alzheimer’s disease: Results from Increased Funding and Outreach
Since 2015, the National Institute on Aging (NIA), the National Institutes of Health (NIH), has experienced a significant increase in funding for Alzheimer’s disease and dementia related to Alzheimer’s disease (AD / ADRD). This analysis assessed the impact of these funds on workforce expansion AD / ADRD. NIA was given 860 awards to 695 AD / grantee ADRD R01 during the fiscal year 2015-2018. Twenty-nine percent of recipients that are new or early stage researchers, while 38% are new to the field of AD research / ADRD (NTF).
NTFS Among these, 59% established researchers, namely, the experts at NIH funding in other disciplines but only for AD / research ADRD. The next award is analyzed to determine the focus of their research is based on the International Alzheimer’s Disease Research Portfolio (IADRP) category. Forty-six percent focused on Molecular Pathogenesis and Physiology. Other IADRP categories, including Diagnosis, Assessment, and Monitoring Disease and Translational Research and Clinical Intervention, representing 5% -15% of the award.
Description: Human frontal lobe tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human frontal lobe tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the frontal lobe tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The frontal lobe tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.
Tissue, Total RNA, Human Disease, Alzheimer's Disease, Postcentral Gyrus, BioGenomics
Description: Human parietal lobe tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human parietal lobe tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the parietal lobe tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The parietal lobe tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.
Description: Human temporal lobe tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human temporal lobe tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the temporal lobe tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The temporal lobe tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.
Description: Human brain temporal lobe tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human temporal lobe tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated brain temporal lobe tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated brain temporal lobe tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.
Total Protein - Alzheimer's Disease: Brain: Amygdala
Significantly, the researchers NTF receive 50%, 42%, and 70% of the total grants awarded in Population Studies, Dementia Care, and Brain Aging, respectively, indicating that the NTF researchers fill research gaps. While these results suggest that increased funding associated with the recruitment of new talent, the opportunities for further growth remain, particularly with regard to treatment, care, and health inequalities.